Latest Pharma and Biotech News
Biotechnology
10 December 2024 Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma.
Today's issue
Refine Search
Biotechnology
Accent Therapeutics, a targeted cancer drug specialist, has announced the appointment of Serena Silver as chief scientific officer, as current CSO and co-founder Robert Copeland retires. 11 December 2024
Biotechnology
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. 11 December 2024
Pharmaceutical
Lynparza (olaparib) partners AstraZeneca and Merck & Co have reported updated findings from the Phase III OlympiA trial in breast cancer, showing a sustained survival benefit. 11 December 2024
Biotechnology
Merck KGaA has appointed Miguel Fernández Alcalde as president of its US biopharmaceutical business, EMD Serono. 11 December 2024
Pharmaceutical
Minoryx Therapeutics, a Spanish biotech specializing in therapies for orphan CNS disorders, will submit for European approval for leriglitazone by the middle of next year. 11 December 2024
Pharmaceutical
Swiss specialty pharmaceutical company Santhera Pharmaceuticals has received approval from the National Medical Products Administration in China for Agamree (vamorolone). 11 December 2024
Biotechnology
Shares of US clinical stage biopharma Candel Therapeutics leapt 166% to $12.25 in pre-market activity today, after it announced results from a multicenter Phase III clinical trial evaluating its CAN-2409 viral immunotherapy in localized prostate cancer patients. 11 December 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has recently become the first Indian company to launch checkpoint inhibitor Zytorvi (toripalimab) in collaboration with Shanghai Junshi Biosciences . 11 December 2024
Biotechnology
US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). 11 December 2024
Biotechnology
Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). 11 December 2024
Biotechnology
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences. 11 December 2024
Pharmaceutical
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research results for its cholesterol lower obicetrapib. 11 December 2024
Biotechnology
Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. 11 December 2024
Biotechnology
Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. 10 December 2024
Biotechnology
BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) space at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2024
Biotechnology
Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. 10 December 2024
Biotechnology
US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). 10 December 2024
Biotechnology
Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130 in Huntington’s disease. 10 December 2024
Biotechnology
Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma. 10 December 2024
Biotechnology
Gilead Sciences has revealed promising five-year data from its Phase II ZUMA-5 trial of Yescarta (axicabtagene ciloleucel), at the American Society of Hematology meeting. 10 December 2024
All news
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series B financing to further advance its portfolio of clinical-stage, nutrient-stimulated hormone (NuSH) analog peptides. 14 November 2024
Biotechnology
Pharma major Bristol Myers Squibb and US biotech Cabaletta Bio are set to present promising Phase I data on CD19-directed CAR-T therapies for severe, refractory lupus at the American College of Rheumatology 2024. 14 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Adaptimmune Therapeutics reported promising data Wednesday from its pivotal Phase II trial of lete-cel in certain solid tumors with few effective treatments. 14 November 2024
Biotechnology
Privately-held Flare Therapeutics, a US biotech targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, has entered into a strategic discovery collaboration with Swiss pharma giant Roche. 14 November 2024
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today posted financial results for the third quarter of 2024, which pleased investors. 14 November 2024
Biotechnology
Shares of US genetic meds company MeiraGTx Holdings were up 7% at $7.12 in early trading after it announced important developments along with its third-quarter 2024 financials, reporting a $0.54 per share loss. 13 November 2024
Pharmaceutical
Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, safety and tolerability of twice-yearly lenacapavir for HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. 13 November 2024
Pharmaceutical
US biotech major Amgen closed 7% lower on Tuesday after investors questioned whether reductions in bone mineral density might be linked to the use of its investigational obesity candidate MariTide (maridebart cafraglutide, formerly AMG 133) in a Phase I trial. 13 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting impressive Phase IIa data this week, but also of its in-silico drug discovery model and the wider artificial intelligence (AI) field. 13 November 2024
Biotechnology
Anglo-American biotech Apollo Therapeutics and China-based Sunshine Lake Pharma have signed an exclusive license agreement to develop APL-18881, a bi-specific fusion protein aimed at treating metabolic diseases. 13 November 2024
Biotechnology
Dutch firm Argenx and China’s Zai Lab have received an approval from the National Medical Products Administration (NMPA) for Vyvgart Hytrulo (efgartigimod alfa). 13 November 2024
Biotechnology
Sanofi has announced that the UK's health technology assessor will conduct a new review of its Sarclisa (isatuximab) combo therapy for relapsed or refractory multiple myeloma. 13 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Pharmaceutical
Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered into a research collaboration and license agreement with Novartis. 13 November 2024
Biotechnology
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. 13 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Danish biopharma company Lundbeck posted a robust 18% revenue increase in the third quarter of 2024, reaching 5.7 billion Danish kroner ($815 million). Earnings per share rose to 0.78 kroner, marking a 15% year-on-year improvement, while adjusted earnings per share increased by 11%. 13 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze